JPWO2020252294A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020252294A5 JPWO2020252294A5 JP2021573841A JP2021573841A JPWO2020252294A5 JP WO2020252294 A5 JPWO2020252294 A5 JP WO2020252294A5 JP 2021573841 A JP2021573841 A JP 2021573841A JP 2021573841 A JP2021573841 A JP 2021573841A JP WO2020252294 A5 JPWO2020252294 A5 JP WO2020252294A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyldiyl
- peg
- immunoconjugate
- pep
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025076031A JP2025118748A (ja) | 2019-06-13 | 2025-05-01 | アミノベンズアゼピン化合物、イムノコンジュゲート、及びそれらの使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962861139P | 2019-06-13 | 2019-06-13 | |
| US62/861,139 | 2019-06-13 | ||
| US202062963884P | 2020-01-21 | 2020-01-21 | |
| US62/963,884 | 2020-01-21 | ||
| PCT/US2020/037477 WO2020252294A1 (en) | 2019-06-13 | 2020-06-12 | Aminobenzazepine compounds, immunoconjugates, and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025076031A Division JP2025118748A (ja) | 2019-06-13 | 2025-05-01 | アミノベンズアゼピン化合物、イムノコンジュゲート、及びそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022537158A JP2022537158A (ja) | 2022-08-24 |
| JP2022537158A5 JP2022537158A5 (https=) | 2023-06-16 |
| JPWO2020252294A5 true JPWO2020252294A5 (https=) | 2023-06-16 |
Family
ID=71608047
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021573841A Ceased JP2022537158A (ja) | 2019-06-13 | 2020-06-12 | アミノベンズアゼピン化合物、イムノコンジュゲート、及びそれらの使用 |
| JP2025076031A Pending JP2025118748A (ja) | 2019-06-13 | 2025-05-01 | アミノベンズアゼピン化合物、イムノコンジュゲート、及びそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025076031A Pending JP2025118748A (ja) | 2019-06-13 | 2025-05-01 | アミノベンズアゼピン化合物、イムノコンジュゲート、及びそれらの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20200390899A1 (https=) |
| EP (1) | EP3983082A1 (https=) |
| JP (2) | JP2022537158A (https=) |
| KR (1) | KR20220034784A (https=) |
| CN (1) | CN114585390A (https=) |
| AU (1) | AU2020291014B2 (https=) |
| BR (1) | BR112021025034A2 (https=) |
| CA (1) | CA3142887A1 (https=) |
| IL (1) | IL288816A (https=) |
| MX (1) | MX2021015221A (https=) |
| TW (1) | TW202112752A (https=) |
| WO (1) | WO2020252294A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102726248B1 (ko) | 2016-07-07 | 2024-11-05 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
| AU2020241686A1 (en) | 2019-03-15 | 2021-11-04 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
| JP2022549510A (ja) * | 2019-09-30 | 2022-11-25 | ボルト バイオセラピューティクス、インコーポレーテッド | アミド結合したアミノベンズアゼピン免疫複合体、及びその使用 |
| CA3155077A1 (en) | 2019-10-25 | 2021-04-29 | Romas Kudirka | Thienoazepine immunoconjugates, and uses thereof |
| IL294818A (en) * | 2020-01-21 | 2022-09-01 | Bolt Biotherapeutics Inc | Anti-pd-l1 antibodies |
| JP7735291B2 (ja) | 2020-02-21 | 2025-09-08 | エーアールエス ファーマシューティカルズ、インコーポレイテッド | ネクチン－４抗体コンジュゲートおよびその使用 |
| CN115996756A (zh) * | 2020-05-08 | 2023-04-21 | 博尔特生物治疗药物有限公司 | 弹性蛋白酶底物肽连接子免疫缀合物及其用途 |
| JP2023532304A (ja) | 2020-07-01 | 2023-07-27 | エーアールエス ファーマシューティカルズ オペレーションズ，インク． | 抗ａｓｇｒ１抗体コンジュゲートおよびその使用 |
| CN116234586A (zh) * | 2020-08-13 | 2023-06-06 | 博尔特生物治疗药物有限公司 | 吡唑并氮呯免疫缀合物及其用途 |
| JP2023552791A (ja) * | 2020-12-11 | 2023-12-19 | ボルト バイオセラピューティクス、インコーポレーテッド | 抗ｈｅｒ２免疫複合体、及びその使用 |
| CN116635084A (zh) * | 2020-12-11 | 2023-08-22 | 博尔特生物治疗药物有限公司 | 抗cea免疫缀合物和其用途 |
| US20220195066A1 (en) * | 2020-12-11 | 2022-06-23 | Bolt Biotherapeutics, Inc. | Anti-cea immunoconjugates, and uses thereof |
| WO2022125908A1 (en) * | 2020-12-11 | 2022-06-16 | Bolt Biotherapeutics, Inc. | Anti-pd-l1 immunoconjugates, and uses thereof |
| US20240091370A1 (en) * | 2020-12-11 | 2024-03-21 | Bolt Biotherapeutics, Inc. | Anti-her2 immunoconjugates, and uses thereof |
| EP4277925A4 (en) * | 2021-01-14 | 2025-06-11 | Gritstone bio, Inc. | Multispecific antibodies and methods of use |
| CA3212926A1 (en) * | 2021-03-26 | 2022-09-29 | Gary Brandt | 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof |
| CN117940168A (zh) * | 2021-03-26 | 2024-04-26 | 博尔特生物治疗药物有限公司 | 2-氨基-4-甲酰胺-苯并氮杂䓬免疫缀合物及其用途 |
| CA3218829A1 (en) * | 2021-05-19 | 2022-11-24 | Zhaolong Tong | Nitrogen-containing compound, conjugate containing said compound, and application thereof |
| CN118475372A (zh) | 2021-10-29 | 2024-08-09 | 博尔特生物治疗药物有限公司 | 具有半胱氨酸突变抗体的tlr激动剂免疫缀合物及其用途 |
| WO2023109944A1 (zh) * | 2021-12-16 | 2023-06-22 | 映恩生物制药（苏州）有限公司 | Tlr调节剂及其用途 |
| TW202339806A (zh) * | 2022-02-09 | 2023-10-16 | 美商博特生物治療公司 | ８—磺醯基—苯并氮呯免疫結合物及其用途 |
| CN118843480A (zh) * | 2022-02-09 | 2024-10-25 | 博尔特生物治疗药物有限公司 | 高分子负载的8-磺酰基-苯并氮杂䓬化合物及其用途 |
| TW202411235A (zh) * | 2022-06-02 | 2024-03-16 | 大陸商映恩生物製藥（蘇州）有限公司 | 一種藥物化合物及其用途 |
| WO2024173387A1 (en) | 2023-02-14 | 2024-08-22 | Bolt Biotherapeutics, Inc. | Aza-benzazepine immunoconjugates, and uses thereof |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US723288A (en) | 1901-10-26 | 1903-03-24 | Harry South Lewis | Cipher-key for cryptographic codes. |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| US5874540A (en) | 1994-10-05 | 1999-02-23 | Immunomedics, Inc. | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
| PT1308456E (pt) | 1998-05-06 | 2007-12-03 | Genentech Inc | Purificação de anticorpos por cromatografia de permuta iónica |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| CA2399940A1 (en) | 2000-04-13 | 2001-10-25 | The Rockefeller University | Enhancement of antibody-mediated immune responses |
| WO2005086875A2 (en) | 2004-03-11 | 2005-09-22 | City Of Hope | A humanized anti-cea t84.66 antibody and uses thereof |
| KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
| LT1976880T (lt) | 2005-12-21 | 2016-10-10 | Amgen Research (Munich) Gmbh | Farmacinės kompozicijos, pasižyminčios atsparumu tirpiam cea |
| EP2144628B1 (en) | 2007-05-08 | 2012-10-17 | Genentech, Inc. | Cysteine engineered anti-muc16 antibodies and antibody drug conjugates |
| MX2010003718A (es) | 2007-10-19 | 2010-04-21 | Genentech Inc | Anticuerpos anti-tenb2 producidos por ingenieria de cisteina y conjugados de farmaco y anticuerpo. |
| HUE025678T2 (en) | 2010-02-04 | 2016-04-28 | Toray Industries | A pharmaceutical composition for the treatment and / or prevention of cancer |
| JP5889912B2 (ja) | 2010-11-17 | 2016-03-22 | ジェネンテック， インコーポレイテッド | アラニニルメイタンシノール抗体コンジュゲート |
| RS56793B1 (sr) | 2011-03-02 | 2018-04-30 | Roche Glycart Ag | Cea antitela |
| US9181348B2 (en) | 2011-08-04 | 2015-11-10 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
| PT2740793T (pt) | 2011-08-04 | 2018-02-23 | Toray Industries | Composição de fármacos para o tratamento e/ou a prevenção de cancro |
| RU2595400C2 (ru) | 2011-08-04 | 2016-08-27 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли |
| PT2740794T (pt) | 2011-08-04 | 2018-06-14 | Toray Industries | Composição farmacêutica para o tratamento e/ou profilaxia de cancro |
| HUE044611T2 (hu) | 2012-02-21 | 2019-11-28 | Toray Industries | Gyógyászati készítmény rák kezelésére |
| PT2818483T (pt) | 2012-02-21 | 2017-10-09 | Toray Industries | Composição medicinal para tratamento e/ou prevenção de cancro |
| US9260513B2 (en) | 2012-02-21 | 2016-02-16 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| BR112014021103A2 (pt) | 2012-02-21 | 2019-10-15 | Toray Industries, Inc | Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo |
| RU2646466C2 (ru) | 2012-07-19 | 2018-03-05 | Торэй Индастриз, Инк. | Метод детекции рака |
| PL2876447T3 (pl) | 2012-07-19 | 2020-05-18 | Toray Industries, Inc. | Sposób wykrywania nowotworu |
| HUE033369T2 (en) | 2012-11-20 | 2017-11-28 | Sanofi Sa | Anti-ceacam5 antibodies and uses thereof |
| ES2704909T3 (es) | 2013-08-09 | 2019-03-20 | Toray Industries | Composición farmacéutica para el tratamiento y/o la prevención del cáncer |
| US9676863B2 (en) | 2014-02-10 | 2017-06-13 | Merck Patent Gmbh | Targeted TGFβ inhibitors |
| MY189836A (en) | 2014-11-21 | 2022-03-11 | Bristol Myers Squibb Co | Antibodies against cd73 and uses thereof |
| EP3233835B1 (en) * | 2014-12-18 | 2019-01-23 | F.Hoffmann-La Roche Ag | Benzazepine sulfonamide compounds |
| KR102581546B1 (ko) * | 2015-03-06 | 2023-09-25 | 에프. 호프만-라 로슈 아게 | 벤즈아제핀 다이카복스아미드 화합물 |
| JP2018532803A (ja) * | 2015-11-02 | 2018-11-08 | ベンティアールエックス ファーマシューティカルズ， インコーポレイテッドＶｅｎｔｉＲｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 癌を処置するためのｔｌｒ８アゴニストの使用 |
| JP6918838B2 (ja) * | 2016-05-23 | 2021-08-11 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 第三級アミド基を有するベンズアゼピンジカルボキサミド化合物 |
| EP3464274B1 (en) * | 2016-05-23 | 2020-05-27 | H. Hoffnabb-La Roche Ag | Benzazepine dicarboxamide compounds with secondary amide function |
| JP7012668B2 (ja) * | 2016-06-12 | 2022-02-14 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | ジヒドロピリミジニルベンズアゼピンジカルボキサミド化合物 |
| KR20240005247A (ko) | 2016-10-28 | 2024-01-11 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| WO2018140831A2 (en) * | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| ES2894731T3 (es) * | 2017-03-15 | 2022-02-15 | Silverback Therapeutics Inc | Compuestos de benzazepina, conjugados y usos de los mismos |
| WO2019084060A1 (en) * | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
| WO2019118884A1 (en) * | 2017-12-15 | 2019-06-20 | Silverback Therapeutics, Inc. | Antibody construct-drug conjugate for the treatment of hepatitis |
| AU2019337654A1 (en) * | 2018-09-12 | 2021-04-08 | Silverback Therapeutics, Inc. | Substituted benzazepine compounds, conjugates, and uses thereof |
| US20200113912A1 (en) * | 2018-09-12 | 2020-04-16 | Silverback Therapeutics, Inc. | Methods and Compositions for the Treatment of Disease with Immune Stimulatory Conjugates |
| WO2020056194A1 (en) * | 2018-09-12 | 2020-03-19 | Silverback Therapeutics, Inc. | Benzazepine compounds, conjugates, and uses thereof |
-
2020
- 2020-06-12 AU AU2020291014A patent/AU2020291014B2/en active Active
- 2020-06-12 EP EP20740106.8A patent/EP3983082A1/en active Pending
- 2020-06-12 CA CA3142887A patent/CA3142887A1/en active Pending
- 2020-06-12 MX MX2021015221A patent/MX2021015221A/es unknown
- 2020-06-12 BR BR112021025034A patent/BR112021025034A2/pt unknown
- 2020-06-12 TW TW109119949A patent/TW202112752A/zh unknown
- 2020-06-12 US US16/900,193 patent/US20200390899A1/en not_active Abandoned
- 2020-06-12 CN CN202080053101.9A patent/CN114585390A/zh active Pending
- 2020-06-12 JP JP2021573841A patent/JP2022537158A/ja not_active Ceased
- 2020-06-12 WO PCT/US2020/037477 patent/WO2020252294A1/en not_active Ceased
- 2020-06-12 KR KR1020227001083A patent/KR20220034784A/ko active Pending
-
2021
- 2021-12-09 IL IL288816A patent/IL288816A/en unknown
-
2025
- 2025-05-01 JP JP2025076031A patent/JP2025118748A/ja active Pending
- 2025-05-09 US US19/203,992 patent/US20250263392A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020252294A5 (https=) | ||
| JP2023002615A5 (https=) | ||
| JP2025131777A5 (https=) | ||
| IL312845B1 (en) | Extacan derivatives, charge-linkers, and their conjugates | |
| JP2024059609A5 (https=) | ||
| JP2019520352A5 (https=) | ||
| RU2018119296A (ru) | Конъюгаты антитела, содержащие агонисты толл-подобного рецептора | |
| HRP20230275T1 (hr) | Antitijelo-lijek konjugati koji sadrže derivate ekteinascidina | |
| CN118973617A (zh) | 缀合物、组合物及使用方法 | |
| HRP20200032T1 (hr) | Antitijelo lijek konjugati | |
| JP2018516243A5 (https=) | ||
| JP2018511628A5 (https=) | ||
| JPWO2019217591A5 (https=) | ||
| JP2025183307A5 (https=) | ||
| WO2010055950A1 (ja) | 癌間質の構成因子に対して特異的結合能を有する物質と抗腫瘍性化合物との複合体による新規の癌ターゲティング治療 | |
| JP2020531430A (ja) | 抗体を標的とする抗ｃｔｌａ４プロボディ療法 | |
| JPWO2021067242A5 (https=) | ||
| JP2025015580A5 (https=) | ||
| JPWO2021081407A5 (https=) | ||
| JPWO2021226440A5 (https=) | ||
| JPWO2020084115A5 (https=) | ||
| JP2021525265A5 (https=) | ||
| JPWO2022087243A5 (https=) | ||
| JPWO2019243159A5 (https=) | ||
| JPWO2022272039A5 (https=) |